NCT05199129View on ClinicalTrials.gov

Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

166

Participants

Timeline

Start Date

November 17, 2021

Primary Completion Date

September 14, 2022

Study Completion Date

September 14, 2022

Conditions
Hypertension
Interventions
DRUG

HCP1904-3

Take once daily for 8 weeks orally

DRUG

RLD2001-1

Take once daily for 8 weeks orally

Trial Locations (1)

03722

Severance Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT05199129 - Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients | Biotech Hunter | Biotech Hunter